Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
Arch Neurol
; 64(3): 377-80, 2007 Mar.
Article
em En
| MEDLINE
| ID: mdl-17353380
ABSTRACT
BACKGROUND:
Although most studies have suggested an increased risk of valvulopathy (primarily regurgitation) with pergolide mesylate use, one study suggested that this problem may also occur with use of the non-ergot-derived dopamine agonists pramipexole dihydrochloride and ropinirole hydrochloride.OBJECTIVE:
To determine if cardiac valve regurgitation occurs more commonly in patients with Parkinson disease (PD) treated with pergolide than in those treated with nonergot agonists at a comparable dose.DESIGN:
A case-control study of echocardiographic findings of valve function in patients receiving dopamine agonists for PD.SETTING:
University-based referral center. Patients Thirty-six patients with idiopathic PD taking pergolide were compared with a matched control group of patients taking nonergot agonists with regard to the frequency and severity of cardiac valve regurgitation. Main Outcome Measure Valve scores (1 indicates trace; 2, mild; 3, moderate; and 4, severe) for the pergolide group were compared with those for the nonergot agonist control group.RESULTS:
The mean +/- SD valve regurgitation scores in the matched pergolide group compared with the nonergot group were as follows aortic, 0.83 +/- 1.23 vs 0.19 +/- 0.53 (P = .01); mitral, 1.42 +/- 1.0 vs 0.39 +/- 0.65 (P<.001); and tricuspid, 1.43 +/- 1.0 vs 0.19 +/- 0.53 (P<.001). Lifetime exposure to a dopamine agonist was not statistically different between the pergolide and nonergot agonist groups (P = .18).CONCLUSIONS:
These data strengthen the conclusion that pergolide contributes to cardiac valve regurgitation when used in the long term as a treatment for PD. There appears to be low risk of cardiac valve regurgitation when using non-ergot-derived dopamine agonists.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Doença de Parkinson
/
Pergolida
/
Doenças das Valvas Cardíacas
/
Antiparkinsonianos
Tipo de estudo:
Evaluation_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article